Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure
- 11 November 1997
- journal article
- clinical trial
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 94 (23) , 12574-12579
- https://doi.org/10.1073/pnas.94.23.12574
Abstract
Potent antiretroviral therapy can reduce plasma HIV RNA levels below the threshold of detection for periods of a year or more. The magnitude of HIV RNA reduction in the lymphoid tissue in patients with suppression of HIV RNA levels in plasma beyond 6 months has not been determined. We evaluated levels of HIV RNA and DNA and characterized resistance mutations in blood and inguinal lymph node biopsies obtained from 10 HIV-infected subjects who received 36–52 weeks of indinavir (IDV)/zidovudine (ZDV)/lamivudine (3TC), IDV, or ZDV/3TC. After 1 year of therapy, viral RNA levels in LN of individuals remained detectable but were log 10 = 4 lower than in subjects on the triple drug regimen with interruption of therapy or in those treated with ZDV/3TC alone, who had viral loads in their lymph nodes indistinguishable from those expected for untreated patients. In all cases viral DNA remained detectable in lymph nodes and peripheral blood mononuclear cells (PBMC). When plasma virus suppression was incomplete, lymph node and PBMC cultures were positive and drug resistance developed. These studies indicate that pronounced and sustained suppression of plasma viremia by a potent antiretroviral combination is associated with low HIV RNA levels in the lymph nodes 1 year after treatment. Conversely, the persistence of even modest levels of plasma virus after 1 year of treatment reflects ongoing viral replication, the emergence of drug resistance, and the maintenance of high burdens of virus in the lymph nodes.Keywords
This publication has 26 references indexed in Scilit:
- Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral TherapyNew England Journal of Medicine, 1997
- Kinetics of Response in Lymphoid Tissues to Antiretroviral Therapy of HIV-1 InfectionScience, 1997
- Antiretroviral effect of zidovudine–didanosine combination on blood and lymph nodesAIDS, 1997
- Quantitative Image Analysis of HIV-1 Infection in Lymphoid TissueScience, 1996
- Viral Load and Immunophenotype of Cells Obtained From Lymph Nodes by Fine Needle Aspiration as Compared with Peripheral Blood Cells in HIV-Infected PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 1996
- Human Immunodeficiency Virus Type 1 Kinetics in Lymph Nodes Compared with PlasmaThe Journal of Infectious Diseases, 1996
- Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working GroupAntimicrobial Agents and Chemotherapy, 1993
- Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDSNature, 1993
- HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of diseaseNature, 1993
- Lymphoid Germinal Centers Are Reservoirs of Human Immunodeficiency Virus Type 1 RNAThe Journal of Infectious Diseases, 1991